Tumor necrosis factor O and its receptors in multiple sclerosis

G. Martino, A. Consiglio, A. Corti, F. L. Sciacca, L. M E Grimaldi

Research output: Contribution to journalArticle

Abstract

We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p

Original languageEnglish
Pages (from-to)77
Number of pages1
JournalItalian Journal of Neurological Sciences
Volume18
Issue number4
Publication statusPublished - 1997

Fingerprint

Multiple Sclerosis
Tumor Necrosis Factor-alpha
Receptors, Tumor Necrosis Factor, Type II
Serum
Messenger RNA
Gadolinium
Blood Cells
Magnetic Resonance Imaging
Recurrence
Brain

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Tumor necrosis factor O and its receptors in multiple sclerosis. / Martino, G.; Consiglio, A.; Corti, A.; Sciacca, F. L.; Grimaldi, L. M E.

In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 77.

Research output: Contribution to journalArticle

@article{990ca425569147bca2087d8d4e2f45e5,
title = "Tumor necrosis factor O and its receptors in multiple sclerosis",
abstract = "We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p",
author = "G. Martino and A. Consiglio and A. Corti and Sciacca, {F. L.} and Grimaldi, {L. M E}",
year = "1997",
language = "English",
volume = "18",
pages = "77",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Tumor necrosis factor O and its receptors in multiple sclerosis

AU - Martino, G.

AU - Consiglio, A.

AU - Corti, A.

AU - Sciacca, F. L.

AU - Grimaldi, L. M E

PY - 1997

Y1 - 1997

N2 - We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p

AB - We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p

UR - http://www.scopus.com/inward/record.url?scp=33746356247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746356247&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746356247

VL - 18

SP - 77

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -